Seattle Genetics Inc
Business Identifier: Monoclonal antibody-based cancer therapeutics.
Public Profile:
Seattle Genetics, Inc. is a clinical stage biotechnology company,focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35 is in pivotal trial stage used for the treatment of patients with relapsed or refractory hodgkin lymphoma. The company’s other product candidates in various stages of clinical trials include SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; dacetuzumab (SGN-40), a humanized anti-CD40 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. The firmhas collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech, Inc.; GlaxoSmithKline LLC; Millennium; and PSMA Development Company LLC. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc.; and Genmab A/S.

 Synopsis: Awardee Business Condition
Year Founded IP Holdings
Employee Range VC funded?
Revenue Range Private/Public
 Most Recent SBIR Projects
Year Phase Agency Dollars Project Title
Potent Monoclonal Antibody Drug Conjugates
Antibody fragment drug conjugates for cancer therapy
Tumor-selective Anticancer Prodrugs
Human Carboxylesterases for Targeted CPT-11 Activation